​
​

Allakos (ALLK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ALLK Stock Forecast

Allakos stock forecast is as follows: an average price target of $109.50 (represents a 10741.58% upside from ALLK’s last price of $1.01) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

ALLK Price Target

The average price target for Allakos (ALLK) is $109.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $218.00 to $1.00. This represents a potential 10741.58% upside from ALLK's last price of $1.01.

ALLK Analyst Ratings

Buy

According to 4 Wall Street analysts, Allakos's rating consensus is 'Buy'. The analyst rating breakdown for ALLK stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Allakos Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 18, 2024Farzin HaqueJefferies$1.00$0.8221.43%-0.99%
Jan 17, 2024Kevin StrangJefferies$3.00$1.19152.10%197.03%
Oct 15, 2021Brian ChengCantor Fitzgerald$218.00$107.48102.83%21484.16%
Row per page
Go to

The latest Allakos stock forecast, released on Jul 18, 2024 by Farzin Haque from Jefferies, set a price target of $1.00, which represents a 21.43% increase from the stock price at the time of the forecast ($0.82), and a -0.99% decrease from ALLK last price ($1.01).

Allakos Price Target by Period

1M3M12M
# Anlaysts--2
Avg Price Target--$2.00
Last Closing Price$1.01$1.01$1.01
Upside/Downside-100.00%-100.00%98.02%

In the current month, the average price target of Allakos stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Allakos's last price of $1.01. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 11, 2024Cowen & Co.HoldHoldHold
Oct 11, 2024Piper SandlerOverweightOverweightHold
Jun 26, 2024Cowen & Co.HoldHoldHold
Jun 26, 2024Piper SandlerOverweightOverweightHold
Dec 18, 2023William Blair-OutperformUpgrade
May 11, 2023Jefferies-BuyUpgrade
Row per page
Go to

Allakos's last stock rating was published by Cowen & Co. on Oct 11, 2024. The company gave ALLK a "Hold" rating, the same as its previous rate.

Allakos Financial Forecast

Allakos Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Allakos's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ALLK's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Allakos EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict ALLK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Allakos's previous annual EBITDA (undefined) of $NaN.

Allakos Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-18.70M$-18.70M$-19.59M$-18.70M$-19.81M$-14.24M$-13.35M$-14.42M$-18.70M$-22.09M$-29.48M
High Forecast$-18.70M$-18.70M$-19.59M$-18.70M$-19.81M$-14.24M$-13.35M$-14.42M$-14.02M$-22.09M$-29.48M
Low Forecast$-18.70M$-18.70M$-19.59M$-18.70M$-19.81M$-14.24M$-13.35M$-14.42M$-22.20M$-22.09M$-29.48M
Surprise %-----------

Allakos's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALLK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Allakos SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Allakos's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ALLK last annual SG&A of $NaN (undefined).

Allakos EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.21$-0.21$-0.22$-0.21$-0.22$-0.16$-0.15$-0.16$-0.21$-0.25$-0.33
High Forecast$-0.21$-0.21$-0.22$-0.21$-0.22$-0.16$-0.15$-0.16$-0.16$-0.25$-0.33
Low Forecast$-0.21$-0.21$-0.22$-0.21$-0.22$-0.16$-0.15$-0.16$-0.25$-0.25$-0.33
Surprise %-----------

According to undefined Wall Street analysts, Allakos's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALLK previous annual EPS of $NaN (undefined).

Allakos Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ALLKAllakos$1.01$109.5010741.58%Buy
FATEFate Therapeutics$2.18$39.671719.72%Hold
ALLOAllogene Therapeutics$2.12$29.001267.92%Buy
SPROSpero Therapeutics$1.16$10.00762.07%Buy
CTMXCytomX Therapeutics$0.89$5.73543.82%Buy
SGMOSangamo Therapeutics$1.96$12.00512.24%Buy
HRTXHeron Therapeutics$1.19$7.00488.24%Buy
SANASana Bio$2.36$8.00238.98%Buy
ARVNArvinas$21.64$71.00228.10%Buy
DAWNDay One Biopharmaceuticals$13.52$38.80186.98%Buy
APLSApellis Pharmaceuticals$28.99$74.50156.99%Buy
ANNXAnnexon$5.46$14.00156.41%Buy
RAREUltragenyx Pharmaceutical$45.13$106.93136.94%Buy
ASMBAssembly Biosciences$15.34$35.50131.42%Buy
NXTCNextCure$1.31$3.00129.01%Buy
RCUSArcus Biosciences$14.51$33.00127.43%Buy
KURAKura Oncology$15.96$26.0062.91%Buy
CRBUCaribou Biosciences$1.99$3.0050.75%Buy
CRNXCrinetics Pharmaceuticals$55.17$70.1427.13%Buy
BPMCBlueprint Medicines$94.60$109.7115.97%Buy
RVMDRevolution Medicines, Inc. Warrant$56.47$60.637.37%Buy
ATRAAtara Biotherapeutics$10.99$10.33-6.01%Sell
KRTXKaruna Therapeutics$329.83$257.50-21.93%Buy
GTHXG1 Therapeutics$7.16$4.50-37.15%Buy

ALLK Forecast FAQ

Is Allakos a good buy?

Yes, according to 4 Wall Street analysts, Allakos (ALLK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of ALLK's total ratings.

What is ALLK's price target?

Allakos (ALLK) average price target is $109.5 with a range of $1 to $218, implying a 10741.58% from its last price of $1.01. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Allakos stock go up soon?

According to Wall Street analysts' prediction for ALLK stock, the company can go up by 10741.58% (from the last price of $1.01 to the average price target of $109.5), up by 21484.16% based on the highest stock price target, and down by -0.99% based on the lowest stock price target.

Can Allakos stock reach $2?

ALLK's average twelve months analyst stock price target of $109.5 supports the claim that Allakos can reach $2 in the near future.

What are Allakos's analysts' financial forecasts?

Allakos's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-61.827M (high $-61.827M, low $-61.827M), average SG&A $0 (high $0, low $0), and average EPS is $-0.695 (high $-0.695, low $-0.695). ALLK's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-75.67M (high $-75.67M, low $-75.67M), average SG&A $0 (high $0, low $0), and average EPS is $-0.85 (high $-0.85, low $-0.85).